Dr Lal PathLabs buys 80% Ghana stake for ₹38 crore

Dr Lal PathLabs completed the acquisition of an 80% stake in Ghana-based Sunshine Healthcare for approximately ₹38 crore. This establishes a new step-down subsidiary to drive its West African diagnostic expansion. The transaction, routed through its Dubai subsidiary, adds a new international revenue stream alongside a recent 70% stake acquisition in Uzbekistan. This matters as it diversifies revenue away from India's highly competitive domestic diagnostic market, backed by a robust ₹1,693 crore cash reserve and a 19.1% YoY Q1 FY27 revenue growth to ₹798 crore. I am watching the Q3 FY27 earnings call for the first consolidated revenue contribution from the Ghana entity and management's commentary on the Uzbekistan integration timeline. The market currently prices Dr Lal PathLabs purely on its domestic market share battles against aggressive tech-led aggregators and standalone labs. What the consensus is missing is the structural valuation re-rating that comes from successful international diversification. At just ₹38 crore, this acquisition is a low-risk, high-optionality probe into West Africa, not a balance sheet strain. By routing this through its Dubai entity, the company optimizes its global tax structure while testing emerging market dynamics. The real catalyst is not the immediate top-line addition, but the proof of concept: if the Ghana and Uzbekistan models yield EBITDA margins comparable to its domestic 31.0%, it unlocks a replicable, capital-light playbook for emerging markets that the market currently does not price into the stock. Accumulate for long-term international margin diversification. Disclosure: I do not hold positions in this stock. This is for educational purposes only and does not constitute investment advice.